GSK announces changes to Vaccines and Global Manufacturing & Supply leadership

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that Luc Debruyne, President, Vaccines, is to leave GSK at the end of the year. Roger Connor, currently GSK’s President, Global Manufacturing & Supply (GMS), will become President, Vaccines on 1 September.

During a 27-year career at GSK, Luc has held a number of roles including General Manager for the Company in the Netherlands and Italy and Senior Vice President of the Pharmaceuticals business in Europe. For the last 5 years he has been President, Vaccines overseeing the successful integration of the Novartis vaccines business, including the R&D portfolios and manufacturing networks, aligning resources to priority projects, preparation of the Shingrix launch and building a stronger presence in the US.

Roger Connor has been on the Corporate Executive Team (CET) since 2012 as President, GMS and has led the strategic transformation of GSK’s supply chain to support improved quality and supply performance. He has a proven track record of leading a complex, global organisation, developing organisational capability and driving cultural transformation.

With effect from 1 September, Regis Simard is appointed President, Pharmaceutical Supply Chain and will join CET. Regis is currently SVP Global Pharma Manufacturing and joined GSK in 2005 as a site director in France, having previously worked in the electronics, medical devices and pharmaceutical industries.

GSK - a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D Principal risks and uncertainties in the company's Annual Report on Form 20-F for 2017.